Pomalidomide in combination with dexamethasone approved for use in refractory multiple myeloma

被引：0
|
作者：
Brown, Emily
机构：
来源：
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2013年 / 2卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：516 / 517
页数：2
相关论文
共 50 条
  • [41] Phase II study of the combination of daratumumab, ixazomib, pomalidomide, and dexamethasone as salvage therapy in relapsed/refractory multiple myeloma
    Kumar, Anupama
    Rosenberg, Aaron
    Padilla, Michelle
    Liu, Lin
    Cheng, Yuwei
    Pittman, Emily
    Tzachanis, Dimitrios
    Larson, Sarah
    Shah, Nina
    Mulroney, Carolyn
    Ball, Edward
    Costello, Caitlin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S174 - S175
  • [42] Phase II study of the combination of daratumumab, ixazomib, pomalidomide, and dexamethasone as salvage therapy in relapsed/refractory multiple myeloma
    Costello, Caitlin
    Ball, Edward
    Mulroney, Carolyn
    Padilla, Michelle
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E360 - E360
  • [43] Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
    Richardson, Paul G.
    Facon, Thierry
    Bensinger, William I.
    Leleu, Xavier
    Campana, Frank
    Mace, Sandrine
    Chiron, Marielle
    van de Velde, Helgi
    Mikhael, Joseph
    BLOOD CANCER JOURNAL, 2021, 11 (03)
  • [44] Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
    Siegel, David S.
    Schiller, Gary J.
    Samaras, Christy
    Sebag, Michael
    Berdeja, Jesus
    Ganguly, Siddhartha
    Matous, Jeffrey
    Song, Kevin
    Seet, Christopher S.
    Talamo, Giampaolo
    Acosta-Rivera, Mirelis
    Bar, Michael
    Quick, Donald
    Anz, Bertrand
    Fonseca, Gustavo
    Reece, Donna
    Pierceall, William E.
    Chung, Weiyuan
    Zafar, Faiza
    Agarwal, Amit
    Bahlis, Nizar J.
    LEUKEMIA, 2020, 34 (12) : 3286 - 3297
  • [45] Real-World Use of Pomalidomide and Dexamethasone in Double Refractory Multiple Myeloma: A Multicentre UK Experience
    Maciocia, Nicola
    Melville, Andrew
    Maciocia, Paul Michael
    Cheesman, Simon
    Sharpley, Faye
    Ramasamy, Karthik
    Streetly, Matthew
    Jenner, Matthew W.
    Benjamin, Reuben
    Schey, Stephen A.
    Popat, Rakesh
    D'Sa, Shirley
    Rismani, Ali
    Yong, Kwee L.
    Rabin, Neil
    BLOOD, 2016, 128 (22)
  • [46] Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma
    Badros, Ashraf
    Hyjek, Elizabeth
    Ma, Ning
    Lesokhin, Alexander
    Dogan, Ahmet
    Rapoport, Aaron P.
    Kocoglu, Mehmet
    Lederer, Emily
    Philip, Sunita
    Milliron, Todd
    Dell, Cameron
    Goloubeva, Olga
    Singh, Zeba
    BLOOD, 2017, 130 (10) : 1189 - 1197
  • [47] Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma
    White, Darrell J.
    Chen, Christine I.
    Baljevic, Muhamed
    Tuchman, Sascha A.
    Bahlis, Nizar J.
    Schiller, Gary J.
    Lipe, Brea
    Kotb, Rami
    Sutherland, Heather J.
    Bensinger, William I.
    Madan, Sumit
    Sebag, Michael
    Lentzsch, Suzanne
    Callander, Natalie S.
    Biran, Noa
    Venner, Christopher P.
    Leblanc, Richard
    Monge, Jorge
    Chubar, Evgeni
    Tadmor, Tamar
    Lavi, Noa
    Leiba, Merav
    De Castro, Andrew
    Van Domelen, Dane R.
    Zhang, Chris
    Mishal, Moran
    Bentur, Ohad S.
    Shah, Jatin J.
    Shacham, Sharon
    Kauffman, Michael G.
    Gasparetto, Cristina J.
    BLOOD, 2021, 138
  • [48] Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
    David S. Siegel
    Gary J. Schiller
    Christy Samaras
    Michael Sebag
    Jesus Berdeja
    Siddhartha Ganguly
    Jeffrey Matous
    Kevin Song
    Christopher S. Seet
    Giampaolo Talamo
    Mirelis Acosta-Rivera
    Michael Bar
    Donald Quick
    Bertrand Anz
    Gustavo Fonseca
    Donna Reece
    William E. Pierceall
    Weiyuan Chung
    Faiza Zafar
    Amit Agarwal
    Nizar J. Bahlis
    Leukemia, 2020, 34 : 3286 - 3297
  • [49] Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma
    Paludo, Jonas
    Mikhael, Joseph R.
    LaPlant, Betsy R.
    Halvorson, Alese E.
    Kumar, Shaji
    Gertz, Morie A.
    Hayman, Suzanne R.
    Buadi, Francis K.
    Dispenzieri, Angela
    Lust, John A.
    Kapoor, Prashant
    Leung, Nelson
    Russell, Stephen J.
    Dingli, David
    Go, Ronald S.
    Lin, Yi
    Gonsalves, Wilson I.
    Fonseca, Rafael
    Bergsagel, P. Leif
    Roy, Vivek
    Sher, Taimur
    Chanan-Khan, Asher A.
    Ailawadhi, Sikander
    Stewart, A. Keith
    Reeder, Craig B.
    Richardson, Paul G.
    Rajkumar, S. Vincent
    Lacy, Martha Q.
    BLOOD, 2017, 130 (10) : 1198 - 1204
  • [50] Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma
    Mark, Tomer M.
    Forsberg, Peter A.
    Rossi, Adriana C.
    Pearse, Roger N.
    Pekle, Karen A.
    Perry, Arthur
    Boyer, Angelique
    Tegnestam, Linda
    Jayabalan, David
    Coleman, Morton
    Niesvizky, Ruben
    BLOOD ADVANCES, 2019, 3 (04) : 603 - 611
12345